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Improves Initial Diagnosis in Emergency Department
Patients With Suspected Acute Coronary Syndromes
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Objectives The aim of this study was to assess the performance of -methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP)
single-photon emission computed tomography (SPECT) to detect acute coronary syndromes (ACS) in emergency
department patients with chest pain.
Background Emergency department diagnosis of chest pain is problematic, often requiring prolonged observation and stress
testing. BMIPP SPECT detects abnormalities in fatty acid metabolism resulting from myocardial ischemia, even
many hours after symptom cessation.
Methods Emergency department patients with suspected ACS were enrolled at 50 centers. Patients received 5 mCi BMIPP
within 30 h of symptom cessation. BMIPP SPECT images were interpreted semiquantitatively by 3 blinded readers.
Initial clinical diagnosis was based on symptoms, initial electrocardiograms, and troponin, whereas the final diagnosis
was based on all available data (including angiography and stress SPECT) but not BMIPP SPECT. Final diagnoses
were adjudicated by a blinded committee as ACS, intermediate likelihood of ACS, or negative for ACS.
Results A total of 507 patients were studied and efficacy was evaluated in 448 patients with sufficient data. The sensi-
tivity of BMIPP by 3 blinded readers for a final diagnosis of ACS and intermediate likelihood of ACS was 71%
(95% confidence interval [CI]: 64% to 79%), 74% (95% CI: 68% to 81%), and 69% (95% CI: 62% to 77%); the
corresponding specificity of BMIPP was 67% (95% CI: 61% to 73%), 54% (95% CI: 48% to 60%), and 70% (95%
CI: 64% to 76%). Compared with the initial diagnosis alone, BMIPP  initial diagnosis increased sensitivity from
43% to 81% (p  0.001), negative predictive value from 62% to 83% (p  0.001), and positive predictive value
from 41% to 58% (p  0.001), whereas specificity was unchanged (61% to 62%, p  NS).
Conclusions The addition of BMIPP data to the initially available clinical information adds incremental value toward the early diag-
nosis of an ACS, potentially allowing determination of the presence or absence of ACS to be made earlier in the eval-
uation process. (Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome [Zeus-ACS];
NCT00514501) (J Am Coll Cardiol 2010;56:290–9) © 2010 by the American College of Cardiology Foundation
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July 20, 2010:290–9 BMIPP Fatty Acid Imaging in Suspected ACSatients presenting to emergency departments (EDs) with
hest pain and other symptoms consistent with an acute
oronary syndrome (ACS) represent a common problem (1,2).
n the absence of high-risk findings, the overall risk is low but
ot negligible. Importantly, this low-risk group of patients
ccounts for nearly two-thirds of ED chest pain patients (3).
ccurately identifying the relatively few high-risk patients
mong this large number of low-risk patients is often
hallenging.
In an effort to accelerate this diagnostic process, a number
f newer tools have been investigated. In this regard, rest
yocardial perfusion imaging (MPI) using technetium
adiopharmaceuticals has been shown to be a valuable
echnique (4). Numerous observational studies and a large
andomized clinical trial demonstrated high accuracy for the
etection of myocardial infarction (MI) and ACS and
avorable effects on clinical decision making (5–9). MPI
dds incremental diagnostic and prognostic value when used
n conjunction with clinical data (5–9).
However, a significant potential limitation of rest MPI
s the ability to detect ischemia in the patient who is
ymptom free at, or shortly after, ED arrival. A newer
maging agent, -methyl-p-[123I]-iodophenyl-pentadecanoic
cid (BMIPP), may have significant utility in this situation.
ree fatty acids are the preferred substrate for high-energy
denosine triphosphate production in the normal myocar-
ium (10–14). In the setting of myocardial ischemia,
igh-energy adenosine triphosphate production shifts from
atty acid metabolism to glucose utilization. This suppres-
ion of fatty acid metabolism may persist long after the
esolution of the perfusion abnormality and ischemia, a
henomenon that has been referred to as ischemic memory.
MIPP is a methyl branched-chain fatty acid that is not
asily metabolized and thus is retained in myocardial cells
15). Clinical studies have demonstrated persistent reduc-
ions in BMIPP uptake long after resolution of ischemic
ymptoms (16–18). Therefore, BMIPP imaging may ex-
end the window of time for identification of myocardial
schemia after symptom resolution, even after restoration of
yocardial blood flow (19).
The purpose of this study was to evaluate the efficacy and
afety of BMIPP in patients who presented to an ED with
ymptoms suggestive of ACS.
ethods
tudy population. Patients eligible for this study were
rawn from those with symptoms consistent with or possi-
ly consistent with ACS who were admitted to an ED at 1
nsight Pharmaceuticals, Molecular Targeting Technologies Inc., National Institutes
f Health, Aptive Imaging, International Atomic Energy Agency (IAEA II), Bracco,
nd GE Healthcare. Dr. Bateman has received research funding from and is on the
dvisory board of Molecular Insight Pharmaceuticals. Dr. Goldman is an employee of
con Medical Imaging.r
Manuscript received October 6, 2009; revised manuscript received February 16,
010, accepted March 9, 2010.f 50 clinical sites in the U.S. and
anada. Patients were 40 years
f age and older; not of child-
earing potential; without a his-
ory of MI; and without ST-
egment elevation, left bundle
ranch block, or Q-wave abnor-
alities on an electrocardiogram
ECG) consistent with previous
I. Patients were excluded if
hey had a left ventricular ejec-
ion fraction40%, serum creat-
nine 2.0 mg/dl; an allergy to
-ray contrast media or iodine/
odides, received any other ra-
iopharmaceutical (other than
ubidium-82 or thallium-201),
r had undergone cardiac stress
esting of any kind within 2 days
efore enrollment in the study. It was required that patients
e imaged with BMIPP within 30 h of the cessation of
ymptoms.
At enrollment, patients were stratified into 1 of 3 risk
trata, high, moderate, or low likelihood of ACS, to ensure
hat a sufficient number of patients who would ultimately be
truth standard positive” would be enrolled. Criteria for
tratification were as follows: patients in the high likelihood
tratum had new or presumably new ST-segment depres-
ion 1 mm on 1 ECG leads consistent with ischemia or
nitial cardiac troponin T or troponin I markers that were
levated above the institution’s diagnostic level for MI.
atients in the moderate likelihood stratum had no features
f the high likelihood group, but a history of coronary artery
isease (CAD), defined as a previous angiography with
50% stenosis or previous revascularization, and symptoms
onsistent with ACS (with an accelerating pattern or
rolonged [20 min] or recurrent episodes at rest or with
inimal effort). Patients in the low likelihood stratum had
o features of the high or intermediate likelihood group,
ad a nonischemic ECG, and either an episode of typical
CS chest pain and related symptoms 20 min without a
istory of CAD or an episode of atypical chest pain
ymptoms 20 min with a history of CAD.
linical and imaging data acquisition. For each partici-
ant, the following data were acquired: assessment of
ymptoms, coronary angiographic data (if clinically indi-
ated), rest/stress SPECT data, cardiac biomarkers, adverse
vents, and BMIPP SPECT images. Angiographic and
PECT images were forwarded to a core laboratory for
valuation by independent readers blinded to patient infor-
ation other than sex, height, and weight. BMIPP images
ere acquired during the course of the patient’s clinical care,
ut per protocol, the BMIPP data were not to be used to
nfluence the clinical course.
MIPP imaging and analysis. Each study patient was to
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BMIPP  -methyl-p-[123I]-
iodophenyl-pentadecanoic
acid
CAD  coronary artery
disease
ECG  electrocardiogram
ED  emergency
department
MI  myocardial infarction
MPI  myocardial perfusion
imaging
SPECT  single-photon
emission computed
tomographyeceive a single injection of 5.0 mCi of BMIPP, containing
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BMIPP Fatty Acid Imaging in Suspected ACS July 20, 2010:290–9p to 0.5 mg of iodofiltic acid, within 30 h of symptom
essation. Imaging was begun within 10 min of BMIPP
njection. For each patient, a total of 60 to 94 tomographic
PECT projections were acquired on a dual-head gamma
amera in an 180° arc from right anterior oblique to left
osterior oblique, using a step-and-shoot technique, over
pproximately 22 min. All raw, unprocessed SPECT data
ere collected from the sites by a central core laboratory.
he core laboratory reconstructed all the raw SPECT data
sing the same filtered back-projection technique and filter
Figure 1 Schematic of Patient Disposition and Analysis Groups
Subcategories not mutually exclusive. ACS  acute coronary syndrome; Angio  a
MPI  myocardial perfusion imaging; PCI  percutaneous coronary intervention; S
of normal.ettings on a single workstation to achieve uniform recon-
truction. All analyses were then performed on the uni-
ormly processed data. Raw data were reconstructed into
ransaxial slices by using filtered back-projection techniques
t the core imaging laboratory. A Butterworth filter (0.5
utoff, 0.5 order) was applied to all patient data using a
iemens Syngo workstation (Siemens Medical Solutions,
alvern, Pennsylvania) and reoriented into short-axis slices.
Three-dimensional left ventricular BMIPP count distri-
utions were analyzed within the QPS (Cedars Sinai Med-
aphy; CABG  coronary artery bypass graft; ECG  electrocardiogram;
summed difference score; TnI  troponin I; TnT  troponin T; ULN  upper limitngiogr
DS 
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July 20, 2010:290–9 BMIPP Fatty Acid Imaging in Suspected ACScal Center, Los Angeles, California) semiautomatic nuclear
ardiology software package. Each patient’s 3-dimensional
ount distribution was quantitatively compared with the
ean normal regional distribution from a sex-matched
ormal database (40 males, 40 females) prospectively devel-
ped in another study (BMIPP SPECT images were
ompleted within 30 h after each normal subject’s stress
CG). The criterion for abnormality in each pixel was2.5
Ds below the mean normal distribution. Three indepen-
ent readers assessed and recorded segmental scores based
n a 5-point scale representing the severity and extent of
bnormality using a 17-segment model (following Ameri-
an Society of Nuclear Cardiology/American College of
ardiology standards) (20), based on visual review of the
atients’ image data, the raw data, and the quantitative
nalysis. Readers were presented with the software-
enerated segmental scores produced by the software pack-
ge and were instructed to use those scores as a guide for
heir visual analysis. However, the readers had to enter their
wn segmental scoring in the electronic case report form.
Based on the earlier phase 2 studies, a cutoff value of 3 for
he summed segmental score of BMIPP was chosen to
uide the blinded readers to optimize diagnostic perfor-
ance. After recording segmental scores, readers were asked
o categorize the image as normal or abnormal.
nalysis of coronary angiographic data. Angiographic
mages were analyzed at a central imaging laboratory,
linded to the BMIPP imaging data. The potential presence
f a culprit lesion was assessed through ulceration and
hrombus severity scoring. The percentage of stenosis and
otential culprit lesion for each of 3 coronary territories
ere based on segmental results within each territory. In
ddition, collateral blood flow was also evaluated for each of
he 3 territories (21–23).
lgorithms for the initial clinical diagnosis. To quanti-
ate the potential value of BMIPP imaging when added to
he initial clinical information, an algorithm for determining
he initial clinical diagnosis was prospectively defined and
as used by an adjudicator (blinded to the BMIPP data) to
eview available initial clinical data and arrive at one of the
ollowing initial diagnoses for each patient: 1) positive for
CS, defined as a positive ECG or troponin at the time of
D admission; 2) equivocal for ACS, defined as at least 1 of
he following criteria: borderline troponin, a borderline
CG, or a negative troponin/negative ECG/positive typical
hest pain symptoms; or 3) negative for ACS, defined as a
egative ECG and troponin and borderline symptoms. For
he calculations of both sensitivity and specificity for the
nitial clinical diagnosis category, equivocal patients were
ounted as incorrect.
djudication of the truth standard for the final diagnosis.
n algorithm for determining the final diagnosis (truth
tandard) was defined prospectively to guide a 2-member
inal Diagnosis Adjudication Committee, which reviewed
atient data independently to determine a final diagnosis
Fig. 1). ACS as a final diagnosis was defined as a positive cardiac troponin on serial testing, 2 mm ST-segment
epression on initial or serial ECGs, and/or a culprit lesion
isible on angiography, as well as patients who had angiog-
aphy showing 90% stenosis, a stress MPI result positive
or inducible ischemia, and/or coronary revascularization,
I, or death during 30 days of follow-up. Disagreements
ere resolved by consensus.
Recognizing that ACS is a syndrome that may be
iagnosed with less clear evidence, a final diagnosis category
f intermediate likelihood of ACS was defined as a subset of
atients with more limited evidence of ACS, such as only
orderline cardiac troponin or angiography showing 70% to
9% stenosis only (no culprit lesion) or a subsequent
ercutaneous coronary intervention with stress MPI nega-
ive or not done.
afety analysis. The safety of BMIPP was evaluated by
omparing baseline and post-injection ECGs, vital signs,
emographic and Baseline Characteristicsf Patients With Signs a d SymptomsACS Dosed With Iodofiltic Acid I 123
Table 1
Demographic and B seline Characteristics
of Patients With Signs and Symptoms
of ACS Dosed With Iodofiltic Acid I 123
Variable
Dosed Population
(N  507)
Sex
Male 275 (54.2)
Female 232 (45.8)
Age (yrs)
Mean (SD) 59.2 (12.2)
Range (minimum, maximum) 30, 97
40 1 (0.2)
40–49 122 (24.1)
50–59 164 (32.3)
60–69 123 (24.3)
70 97 (19.1)
Race
White 393 (77.5)
Black 83 (16.4)
Other (Asia Pacific, American Indian) 30 (5.9)
Ethnicity
Hispanic or Latino 66 (13.0)
Not Hispanic or Latino 441 (87.0)
Weight (kg)
Mean (SD) 87.4 (21.0)
Range (minimum, maximum) 47, 166
History of
CAD 102 (20.1)
CABG 36 (7.1)
HTN 353 (69.6)
Diabetes 139 (27.4)
Cardiac medication
Aspirin 440 (86.8)
Beta-blockers 322 (63.5)
ACEIs 185 (36.5)
Nitrates 312 (61.5)
Any of the above 471 (92.9)
alues are n (%) unless otherwise indicated.
ACEI  angiotensin converting enzyme inhibitor; ACS  acute coronary syndrome; CABG 
oronary artery bypass grafting; CAD  coronary artery disease; HTN  hypertension.
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BMIPP Fatty Acid Imaging in Suspected ACS July 20, 2010:290–9nd clinical laboratory measurements. Patients were moni-
ored for adverse events from the time informed consent was
igned through 20 to 30 h after administration of BMIPP
nd were followed for up to 30 days to collect data for any
erious adverse events, subsequent stress perfusion studies,
r intervening cardiac events.
ata and statistical analysis. Sensitivity and specificity
or the analysis of BMIPP SPECT images alone, for the
nitial clinical diagnosis alone, and the initial clinical
iagnosis plus the BMIPP SPECT imaging result each
ere calculated in comparison with the truth standard for
CS. The added clinical utility of BMIPP SPECT
maging for patients with symptoms suggestive of ACS
as determined by comparing the improvement in diag-
ostic accuracy obtained by including the interpretation
f BMIPP SPECT imaging results, along with clinical
ata available at presentation, when making the diagnosis
nd then comparing these results with the diagnostic
ccuracy attained using initial clinical data alone, using
cNemar’s test of paired proportions (24). The statisti-
al significance of the comparisons for positive and
egative predictive values between the 2 diagnostic strat-
gies was assessed using the bootstrap resampling method
ia 5,000 simulations (25). Net reclassification improve-
ent was calculated based on the method proposed by
ercina et al. (26). For all estimates, a 95% confidence
nterval (CI) (exact binomial distribution) was calculated.
Performance Characteristics for the Initial ClinicBMIPP Alone, and th Combination of the InitiaSPECT Imaging (P ti nts With Majority Read fo
Table 3
Performance Char c eristics for he
BMIPP Alone, and the Combination
SPECT Imaging (Patients With Majo
Diagnostic
Mode
ACS Pos
(Negative
Sensitivity Spec
InDx 42.9 (35.0–50.9) 60.9 (54
BMIPP alone 73.0* (65.9–80.1) 63.2 (57
InDx  BMIPP 81.0* (74.7–87.3) 61.7 (55
Values are % (95% confidence interval). Compared with initial diagnosi
specificity. Bootstrap method (5,000 simulations) was used for NPV a
Majority read will be missing for a number of images (n  32) when 
ensitivity and Specificity for BMIPP SPECT Images for the EfficacTable 2 Sensitivity and Specificity for BMIPP SPECT Images fo
Variable (by ACS Category) 1
Sensitivity
ACS (n  129) 75.9 (88/116), 67.6–84.1 78.
ACS and intermediate likelihood ACS
(n  175)
71.3 (114/160), 63.9–78.6 74.
Specificity
Negative ACS (n  273) 66.8 (165/247), 60.7–72.9 54.
alues are % (n/N), 95% confidence interval. The denominator is different for each reader and for
rror during image processing were excluded for each reader. The majority read was determined ba
2 readers rated it as nondiagnostic or with constrain error or 1 reader rated the image as nond
BMIPP  -methyl-p-[123I]-iodophenyl-pentadecanoic acid; SPECT  single-photon emission cowhereas the other readers’ results were discordant.
InDx  initial diagnosis; NPV  negative predictive value; PPV  positive pesults
tudy population. Table 1 summarizes patient demo-
raphic and baseline characteristics for all dosed patients
n  507); 3 enrolled patients were not dosed, 2 due to
navailability of study radiopharmaceutical.
Figure 1 shows the patient disposition for both safety and
fficacy populations. To be included in the efficacy analysis,
ach patient must have had sufficient data available for the
inal Diagnosis Adjudication Committee to make a definite
nal diagnosis. Of the 507 dosed patients, 59 were excluded
rom analysis. Five patients had a protocol exclusion criteria
iolation, 4 patients did not complete BMIPP SPECT imag-
ng, and 54 patients did not have angiography or protocol-
pecified stress MPI during the 30-day follow-up period.
hese categories were not mutually exclusive. The efficacy
opulation consisted of 448 patients who underwent BMIPP
PECT imaging and received an adjudicated final diagnosis
rom the Final Diagnosis Adjudication Committee.
fficacy of BMIPP SPECT imaging. BMIPP SPECT
maging was performed at a mean of 11.9  9.8 h after
essation of symptoms. Time of chest pain cessation was
vailable for 433 patients. Imaging was performed 12 h
fter chest pain cessation for 46%, between 0 to 12 h for
2%, and while chest pain was ongoing in 2% of patients.
f 448 BMIPP images in the efficacy population, image
uality was rated as excellent, good, or diagnostic in 96% to
9% of cases across the 3 blinded readers.
iagnosis Alone, Results Withical Diagnosis and BMIPPIPP SPECT) (n  416)l Clinical Diagnosis Alone, Results With
e Initial Clinical Diagnosis and BMIPP
Read for BMIPP SPECT) (n  416)
n  188), Negative (n  298)
nd ACS Intermediate Likelihood)
NPV PPV
.1) 62.3 (56.1–68.6) 41.4 (33.7–49.1)
.4) 78.4* (72.5–84.3) 56.1† (49.2–63.0)
.8) 83.4* (77.8–89.0) 57.6* (51.0–64.3)
: *p 0.001; †p 0.01. McNemar’s test was used for sensitivity and
. Majority read of BMIPP was determined by 2 of 3 blinded readers.
r considered an image nondiagnostic or to have a constraining error,
ulation (n  448)Efficacy Population (n  448)
Reader
2 3 Majority Read
127), 70.3–85.6 74.8 (86/115), 66.4–83.2 76.3 (90/118), 68.2–84.4
/172), 67.6–81.2 69.4 (111/160), 61.9–76.8 73.0 (119/163), 65.9–80.1
/272), 47.9–60.2 69.6 (172/247), 63.7–5.6 63.2 (160/253), 57.1–69.4
jority read because images assessed by each reader as nondiagnostic or with constrain/contour
the consensus of 2 of the 3 readers. The majority read was undetermined for a study image when
ic and 2 other readers disagreed.
tomography; other abbreviation as in Table 1al Dl Clinr BMIniti
of th
rity
itive (
ACS a
ificity
.7–67
.1–69
.5–67
s alone
nd PPV
1 readey Popr the
0 (99/
4 (128
0 (147
the ma
sed onredictive value; other abbreviations as in Tables 1 and 2.
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July 20, 2010:290–9 BMIPP Fatty Acid Imaging in Suspected ACSPerformance characteristics for each individual blinded
eader for overall diagnosis and for each subcategory of ACS
iagnosis are shown in Table 2. For the diagnosis of ACS,
he sensitivities for each reader as well as the majority read
ere 75% to 80%.
Table 3 summarizes sensitivity and specificity results
or the initial clinical diagnosis alone, for BMIPP
PECT imaging alone (based on the majority read), and
or the initial clinical diagnosis with the added informa-
ion from BMIPP SPECT imaging. For the diagnosis of
CS, BMIPP SPECT imaging alone provided higher
ensitivity than the initial clinical diagnosis alone (73%
s. 43%, p  0.001). Combining information from both
he initial clinical diagnosis and BMIPP SPECT images
esulted in significantly higher sensitivity (81%, McNe-
ar’s test, p  0.001) compared with the sensitivity
43%) for the initial clinical diagnosis alone. This in-
rease in sensitivity was associated with no change in
pecificity because the specificity of BMIPP SPECT
maging alone was similar to that of the initial clinical
iagnosis alone (63% vs. 61%, respectively). The speci-
city of the combination of initial clinical information
nd BMIPP SPECT imaging was also similar (62%).
he negative predictive value increased significantly,
rom 62% for the initial clinical diagnosis alone to 83%
or the combined initial clinical information and BMIPP
PECT imaging (p  0.001). The positive predictive
alue increased as well, from 41% for the initial clinical
iagnosis alone to 58% when BMIPP SPECT imaging
esults were added (p  0.001).
Among all patients, net reclassification improvement was
.5% (p  0.13 vs. 0%), and among those patients whose
nitial clinical diagnosis was equivocal or negative, the net
eclassification improvement was 32% (p  0.001 vs. 0%).
orrelation of BMIPP imaging with coronary angiography
nd culprit lesion anatomy. A subgroup analysis was
erformed to assess the performance of BMIPP SPECT
maging among those patients who underwent angiography
n  198), stratified by the presence/absence of a potential
ulprit lesion and the presence/absence of collateral blood
ow (Table 4). BMIPP SPECT imaging had sensitivities
or ACS with a culprit lesion present of 84% to 86% across
he 3 readers. When these data were stratified by the presence/
bsence of collateral blood flow, the sensitivities were 90% to
6% when collateral blood flow was absent and 75% to 82%
hen collateral blood flow was present (Figs. 2 and 3). The
ensitivities of BMIPP were lower for ACS without a
ulprit lesion present: 57% to 74%, across 3 readers, for any
tenosis 70% but without angiographic features of a
ulprit lesion.
nfluence of duration from cessation of symptoms on
MIPP performance. Among patients who were im-
ged with BMIPP 12 h after symptom resolution,
ensitivity for detection of the truth standard final diag-
osis was 77.1% (95% CI: 66.6% to 87.7%) based on the Ev
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BMIPP Fatty Acid Imaging in Suspected ACS July 20, 2010:290–9ajority read, whereas among patients who were imaged
2 to 30 h after symptom resolution, sensitivity was
8.6% (95% CI: 58.2% to 79.0%) based on the majority
ead. The receiver-operator characteristic curve assessing
he ability of BMIPP imaging to discriminate the pres-
nce and absence of the ACS truth standard, with
atients classified as those imaged 12 h versus those
maged 12 h after symptom resolution, is shown in
igure 4. The area under the receiver-operator charac-
eristic curve was similar for both groups (for 12 h, the
rea under the curve  0.710; for 12 h, the area under
he curve  0.714).
afety of BMIPP. Of 507 patients who received BMIPP,
09 patients (21.5%) reported a total of 209 adverse events.
f these, 164 (78.5%) events were judged by the physician
o be unrelated to BMIPP use. Most adverse events were
ild in severity. Serious adverse events were reported by 27
5.3%) patients, and 4 deaths (lung cancer, MI, cardiac
rrest, progressive CAD) occurred during the study or
ithin the 30-day follow-up period after dosing with
MIPP (none were attributed by the investigators to
MIPP).
The most common adverse event was headache (3.9% of
atients); none were rated severe, and most (17 of 20) were
ttributed to BMIPP administration by the investigators.
linical laboratory values and vital signs showed only
linically insignificant changes from baseline after BMIPP
Figure 2 Angiographic Image From
a Male Patient With an ACS
Angiography demonstrated stenosed left circumflex coronary artery with 89%
stenosis and potential culprit lesion features. Inset: Magnification of the steno-
sis. Abbreviation as in Figure 1.osing. iiscussion
he current trial was carried out in contemporary ED
ractice, assessing patients presenting with chest pain symp-
oms suggestive of an ACS. The results suggest that
ssessing fatty acid metabolism with BMIPP SPECT im-
ging has overall sensitivity comparable to that of other
maging modalities in use for this situation and also adds
ncremental diagnostic value to the initial clinical informa-
ion available to clinicians. Moreover, taking advantage of
he concept of ischemic memory—the prolonged suppres-
ion of fatty acid metabolism after an episode of ischemia—
MIPP imaging seems to maintain sensitivity even when
erformed hours after the ischemic symptoms have resolved.
he direct imaging of the metabolic consequence of tissue
schemia and the ability to capture such data many hours
fter symptom cessation are unique properties.
The feasibility of using metabolic imaging to detect
schemic myocardium was first demonstrated by Schelbert
t al. (27) in a canine model. In the ischemic segments, they
bserved a decrease in fatty acid utilization (assessed by
-11 palmitate) and an increase in glycolytic flux (assessed
y fluorodeoxyglucose positron emission tomography). In
ubsequent occlusion-reperfusion studies in canines,
chwaiger et al. (28) showed prolonged metabolic alteration
fter 30 min of coronary occlusion that persisted for several
eeks thereafter. These studies served as the experimental
asis of subsequent clinical studies in human subjects for
sing metabolic imaging (fluorodeoxyglucose and BMIPP)
o identify antecedent ischemia (19,29–32).
Among 111 patients presenting to an ED with acute
hest pain who underwent coronary angiography, Kawai et
l. (30) reported a sensitivity of BMIPP SPECT imaging of
4% to detect obstructive coronary stenosis or provocable
pasm, when BMIPP imaging was performed within 3 days
f symptoms. The results of the present study are consistent
ith those data, generalizing the concept to a larger number
f patients studied in multiple centers. In the Kawai et al.
30) study, however, the prevalence of disease was high (as
ight be expected among a group of patients who under-
ent angiography). The current study includes a broader
ange of patients in contemporary practice and uses the final
linical diagnosis of ACS as the truth standard because not
ll patients underwent angiography on clinical grounds. It is
f interest that the sensitivity of BMIPP imaging in the
resent trial, when assessed based on an angiographic
tandard in patients with signs of a culprit lesion without
ollaterals, is 90% among several readers.
The sensitivity data reported herein are similar to other
ata (33) for rest perfusion imaging when MPI was com-
ared with a truth standard using a troponin definition. The
urrent specificity data are also similar to those reported in
ome of the larger observational series of ED patients
tudied with rest MPI (6,7). However, it should be noted
hat the sensitivity of rest MPI is dependent on isotope
njection being performed while there is decreased coronary
fl
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July 20, 2010:290–9 BMIPP Fatty Acid Imaging in Suspected ACSow or a prolonged post-ischemic wall motion abnormality.
n clinical studies of MPI for this purpose, patients present-
ng 3 h after symptom resolution (9), or in some studies
6 h after symptom resolution (6,8), are excluded. The
revalence of perfusion abnormality has been shown to
iminish with time after an experimental ischemic insult in
n animal model of PCI-induced ischemia (34).
In contrast to these studies, in the present study, patients
ere included if the isotope could be injected up to 30 h
fter symptom cessation. This time criterion was based in
art on a preliminary study comparing BMIPP imaging
ith stress-induced ischemia on stress MPI studies (19).
rom the current data, it is demonstrated that the sensitivity
f BMIPP imaging is maintained even many hours after
ymptom resolution (Fig. 4). This represents a potentially
mportant clinical advantage in that the use of BMIPP
maging may substantially extend the time window within
hich noninvasive imaging of the effects of ischemia on the
yocardium may assist in the evaluation of patients with
uspected ACS.
In patients who may present late after symptom cessation,
he time course of biomarker elevation would suggest that a
ingle determination many hours after symptom cessation
Figure 3 Example of BMIPP SPECT Imaging in a Patient With S
-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) single-photon emission co
a large defect is observed with BMIPP in the lateral wall, consistent with the steno
angiogram.hould be sufficient to rule out myocardial necrosis (8) and sotentially allow patients to proceed directly to stress
erfusion imaging. To the extent that performance charac-
eristics of BMIPP imaging are confirmed in subsequent
rials, a single rest BMIPP image to assess for recent
schemia may answer the clinically relevant questions at
and without the need for stress testing. This concept could
e tested in future trials.
The choice of a truth standard with which to compare
oninvasive tests in the ED setting has been variable in
he published literature. Many previous studies of imag-
ng tests in this setting have used MI, often based on a
reatine kinase based definition, as the truth standard
6,7). Other studies have used a composite of MI or
evascularization (the latter acting as a surrogate for
nstable angina) (5,7,8), whereas others have used an
ngiographic standard of coronary stenosis (26). In the
resent trial, a truth standard of the final clinical diag-
osis of ACS was used to capture the diagnosis for which
he imaging is intended and which the evaluating clini-
ian is most interested in ruling in or ruling out. An
ttempt was made to use all available clinical information
ut to 30 days of follow-up to inform the adjudication of
he truth standard. Nonetheless, ACS remains a clinical
cted ACS
d tomography (SPECT) images from the same patient shown in Figure 2;
d the potential culprit lesion seen in the left circumflex coronary artery on theuspe
mpute
sis anyndrome and not a disease per se. In some cases, the
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BMIPP Fatty Acid Imaging in Suspected ACS July 20, 2010:290–9iagnosis is clear, as in a patient with troponin elevation
nd who has an angiogram with an apparent culprit
esion. In others, however, the distinction between ACS
nd not ACS is more speculative. For a patient present-
ng with a chest pain syndrome without ECG changes or
iomarker elevation on serial testing who then has a
ositive stress test result, the diagnosis of CAD is
pparent, but whether the scenario represents an ACS at
he time of ED presentation is less clear. The reduction
n sensitivity as less certain categories of ACS are
ntroduced reinforces this concept (Table 2).
tudy limitations. The patient population sample repre-
ents a nonconsecutive observational population sample of
atients consenting to be included in the trial. The preva-
ence of ACS is higher than in other purely observation
eries of patients undergoing imaging on clinical grounds
5–8) and in other trials (9). This is in large part protocol
riven in the current trial by the requirement in this study
or a certain percentage of patients to be in the high
ikelihood stratum who had initial positive troponin or
lectrocardiogram changes. This study design feature was
ncorporated to ensure that a sufficient number of patients
ho would ultimately be truth standard positive would be
nrolled to allow a reasonably rigorous estimation of sensi-
ivity. Such patients may not require imaging in clinical
Figure 4
Receiver-Operator Characteristic
Curves for Patients Imaged <12 h
Versus 12 to 30 h After Symptom Resolution
Patients are divided by whether symptoms resolved 0 to 12 h before imaging
(open circles) or 12 to 30 h before imaging (open squares). The area under
the receiver-operator characteristic curve was similar for both groups (for
12 h, the area under the curve  0.710; for 12 h, the area under the
curve  0.714).ractice. Also, approximately 10% of the patients did notave sufficient information to make a final diagnosis and
ere prospectively excluded from the analysis of BMIPP
erformance characteristics.
There are strengths to the analysis. BMIPP imaging
as performed in many more centers than had been
reviously reported in trials, with diagnostic image qual-
ty in the vast majority of patients. Image analysis was
erformed in the rigorous analytic environment consis-
ent with U.S. Food and Drug Administration guidance
or analysis of images in clinical trials (35), and quanti-
ative data from a radionuclide- and sex-matched data-
ase specific for BMIPP were available to readers.
onclusions
maging fatty acid metabolism with BMIPP SPECT in ED
atients with suspected ACS has sensitivity similar to that
f other contemporary imaging modalities, although it has
he unique property of maintaining sensitivity even when
erformed up to 30 h after symptom resolution. The
ddition of BMIPP data to the initially available clinical
nformation adds incremental value for the early diagnosis
f an ACS, potentially allowing determination of the
resence or absence of an ACS to be made much earlier in
he evaluation process.
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